A protein fragment already circulating in your bloodstream just reversed three of Alzheimer's most damaging hallmarks at once — in mice, using a mechanism no single prior drug has managed to hit simultaneously.

  • 3 disease pathways targeted at once: tau tangles, amyloid plaques, and brain inflammation
  • Treated mice showed measurably better memory and motor function than untreated mice
  • The peptide, catestatin (CST), is cut from a protein the human body already makes
  • Findings published in the peer-reviewed journal Molecular Therapy

A Molecule Your Body Already Makes

Alzheimer's disease and related neurodegenerative disorders remain among medicine's most stubborn problems, slowly stripping away memory, movement, and independence. Researchers at UC San Diego School of Medicine tested catestatin, a small peptide fragment, in mice bred to develop Alzheimer's-like disease.

CST is derived from chromogranin A, a protein the body uses to store and release hormones and neurotransmitters. That matters because it means the raw material for a potential therapy may already be built into normal human biology, rather than something synthesized from scratch in a lab.

The team found that CST reduced buildup of both tau and amyloid-beta, the two misfolded proteins long blamed for killing neurons in Alzheimer's patients. It also dialed down neuroinflammation, a third driver of cognitive decline that most single-target drugs ignore entirely.

Hitting Several Problems With One Molecule

Most experimental Alzheimer's drugs are built to block one protein or one pathway, and most have failed in human trials for exactly that reason — the disease rarely has a single cause. CST's apparent advantage is that it acts across several of those broken systems at once, rather than isolating just one.

"Our findings show that CST can act across several of these disease-associated pathways and shift the brain toward a healthier state," said Sushil K. Mahata, PhD, senior author and professor of medicine at UC San Diego School of Medicine.

Lead author Suborno Jati, PhD, a postdoctoral scholar on the project, said the team is now investigating whether CST can also change how brain cells produce and use energy — a shift that could make neurons more resistant to the cellular stress that drives neurodegeneration in the first place. That line of research could matter as much as the protein-clearing results, since energy failure inside aging neurons is increasingly seen as an early trigger for disease, not just a side effect.

What Happens Next

The results are preclinical, meaning they come from mice, not people. Researchers caution that CST's safety and correct human dosing still need to be established before anyone can test it as an actual Alzheimer's treatment, and that process typically takes years of additional study.

Still, the multi-pathway approach is notable. CST's broader activity has already been linked to cardiovascular, metabolic, and immune regulation in earlier research, suggesting the peptide operates inside a wide network of body systems rather than flipping one isolated switch. If a therapy built on CST — or synthetic peptides modeled after it — eventually clears human safety trials, it could offer a genuinely different strategy for a disease that has resisted single-target drugs for decades.

Mahata is listed as founder of CgA Therapeuticals, Inc. and co-founder of Siraj Therapeutics; he and Jati are co-inventors on intellectual property tied to the findings. The study was supported in part by the National Institutes of Health and the U.S. Department of Veterans Affairs, and was first reported by UC San Diego School of Medicine. Full findings appear in Molecular Therapy.